Clinical Trial

Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to describe participants characteristics that can predict the safety and effectiveness of cladribine tablets, as assessed by time-to-discontinuation of treatment with cladribine tablets, and to assess other patient-reported, clinical, and imaging outcomes in participants with relapsing multiple sclerosis (RMS) in the long term, in a real-world setting.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2023-03-22; most recent amendment 2026-05-21.
Status change: Recruiting → Active, Not Recruiting 2025-04-08
Status change: Not Yet Recruiting → Recruiting 2023-10-26
Trial Details
NCT Number NCT05797740
Lead Sponsor Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Conditions Multiple Sclerosis
Enrollment 366 participants
Start Date 2023-08-03
Primary Completion 2029-01-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-07